- Author(s):
- Organization(s):
Lonza
Developers must carefully evaluate the device, formulation and capsule, as well as the interactions among them.
Because DPIs are a drug/device combination product, there are three critical components within the overall product that developers must select and evaluate: the device, the formulation and (when using a capsule-based inhaler) the capsule itself. These components form what may be called “the DPI interaction triangle.” Using a risk-based approach that ensures the appropriate technologies are selected for the three components can be the best path to success.